Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give Vor Biopharma a consensus “Moderate Buy” rating: six analysts recommend buying, two strongly recommend buying, two advise holding, and one recommends selling. The average 12-month price target is $42.25.
• VOR shares opened at $23.67, compared with a 12-month trading range of $6.50 to $50.20. Recent analyst actions included Jefferies upgrading the stock to “strong buy” and Wedbush raising its target price to $18 while maintaining a neutral rating.
• Institutional ownership stands at 97.29%, with major investors including RA Capital Management and Fcpm III Services substantially increasing their positions. Vor is developing genome-edited, allogeneic cell therapies, led by its VOR33 candidate for relapsed or refractory AML and high-risk MDS.

Shares of Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $42.25.

A number of equities research analysts recently weighed in on VOR shares. Jefferies Financial Group raised shares of Vor Biopharma to a "strong-buy" rating in a report on Thursday, April 30th. Weiss Ratings upgraded shares of Vor Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, June 30th. Wall Street Zen cut shares of Vor Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Wedbush raised their target price on Vor Biopharma from $15.00 to $18.00 and gave the company a "neutral" rating in a research note on Thursday, May 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th.

Vor Biopharma Price Performance

VOR stock opened at $23.67 on Friday. The stock has a 50-day moving average price of $17.62 and a two-hundred day moving average price of $15.80. Vor Biopharma has a 12-month low of $6.50 and a 12-month high of $50.20.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that Vor Biopharma will post -2.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. increased its stake in Vor Biopharma by 172.7% during the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company's stock valued at $70,697,000 after purchasing an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. lifted its position in shares of Vor Biopharma by 852.8% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company's stock worth $47,315,000 after buying an additional 3,237,714 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Vor Biopharma in the 4th quarter valued at about $33,275,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Vor Biopharma in the 4th quarter valued at about $22,890,000. Finally, NEXTBio Capital Management LP bought a new stake in shares of Vor Biopharma during the 4th quarter valued at about $13,080,000. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source